Nancy A. Hong, Ph.D.
San Diego, California
Joined in 2016
The RiverVest team has so much dedication and discipline. You need both of these traits to identify and nurture life science innovations with the best odds of impact.
Nancy joined RiverVest in 2016 and focuses on both biopharmaceutical and medical device opportunities, contributing to the formation, development and strategic direction of RiverVest portfolio companies. Currently, Nancy serves as a member of the Board of Directors at Scout Bio, Inc., Blue Jay Therapeutics, Sequre Dx, and Biolinq, Inc. She formerly was a member of the Board of Directors at Xilio Therapeutics. (NASDAQ: XLO)
Previously, Nancy was a principal with BioMed Ventures, where she originated and managed successful investments in therapeutics, diagnostics and medical devices. Prior to BioMed, she was an investment professional at Forward Ventures and served as an advisor to biotech and pharmaceutical companies entering new areas of research. Nancy started her career as a scientist at Phenomix, a venture-backed discovery biotech company in San Diego.
Trained in the areas of immunology and oncology, Nancy earned a B.S. with honors in Biology from the California Institute of Technology and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She conducted postdoctoral training at the University of California, San Francisco, as a fellow of the Leukemia & Lymphoma Society.
Personal Interests: food, movies, yoga, hiking, travel, and the arts
In July 2019, representing San Diego in a group of biotech investors and executives, Nancy climbed Mount Kilimanjaro, the highest point in Africa, while raising awareness and funds for basic and translational cancer research.
St. Louis, San Diego & Cleveland
Collaborative Approach and Open Communication
An exceptional firm culture where each is expected to be transparent, strategic, dependable, results-driven, collaborative, and grounded in purpose. That's RiverVest.